Literature DB >> 12537692

Enhancement of endotoxin activity by muramyldipeptide.

Haruhiko Takada1, Shigekuni Yokoyama, Shuhua Yang.   

Abstract

Synthetic muramyldipeptide (MDP), the minimum structural moiety of bacterial peptidoglycan for adjuvant and related activities, sensitized mice for two types of lethal shock induced by lipopolysaccharide (LPS): an early anaphylactoid shock and late endotoxin shock. In relation to the late reaction in MDP-primed mice, enhanced production of inflammatory cytokines was induced in response to various bacterial components. MDP showed a priming effect in mice not only when administered parentally but also via the oral route. MDP activated human monocytic THP-1 cells in a CD14-, Toll-like receptor 2 (TLR2)- and TLR4-independent manner to increase expression of MyD88, a common adaptor and signaling molecule for TLRs, and exhibited synergistic cytokine inducing effects with TLR4 agonists (LPS, synthetic lipid A), TLR2 agonist (synthetic lipopeptide), and TLR9 agonist (bacterial CpGDNA) in THP-1 cells in culture. Consistent with these findings, MDP primed TLR2 knockout mice as well as wild-type controls, but not TLR4-mutated C3H/HeJ mice, to enhance production of tumor necrosis factor-alpha upon stimulation with synthetic lipid A. In contrast to the BCG- and Propionibacterium acnes-priming system, MDP primed mice in an interferon-gamma-independent manner. Further studies are required to elucidate the mechanisms of the synthetic and priming activities of MDP for various bacterial components.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12537692     DOI: 10.1179/096805102125000669

Source DB:  PubMed          Journal:  J Endotoxin Res        ISSN: 0968-0519


  9 in total

1.  Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells.

Authors:  Hiroyuki Tada; Setsuya Aiba; Ken-Ichiro Shibata; Toshiaki Ohteki; Haruhiko Takada
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

2.  Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy.

Authors:  Chikako Ogawa; Yuen-Joyce Liu; Koichi S Kobayashi
Journal:  Curr Bioact Compd       Date:  2011-09

3.  Proteasomal degradation of Nod2 protein mediates tolerance to bacterial cell wall components.

Authors:  Kyoung-Hee Lee; Amlan Biswas; Yuen-Joyce Liu; Koichi S Kobayashi
Journal:  J Biol Chem       Date:  2012-09-27       Impact factor: 5.157

4.  Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B.

Authors:  Dongmei Lu; Lucila Garcia-Contreras; Ding Xu; Sherry L Kurtz; Jian Liu; Miriam Braunstein; David N McMurray; Anthony J Hickey
Journal:  Pharm Res       Date:  2007-07-27       Impact factor: 4.200

5.  Muramyl dipeptide enhances lipopolysaccharide-induced osteoclast formation and bone resorption through increased RANKL expression in stromal cells.

Authors:  Masahiko Ishida; Hideki Kitaura; Keisuke Kimura; Haruki Sugisawa; Tomo Aonuma; Haruhiko Takada; Teruko Takano-Yamamoto
Journal:  J Immunol Res       Date:  2015-04-27       Impact factor: 4.818

6.  Current knowledge and future directions of TLR and NOD signaling in sepsis.

Authors:  Niamh M Foley; Jian Wang; H Paul Redmond; Jiang Huai Wang
Journal:  Mil Med Res       Date:  2015-01-07

7.  Effects of Ginkgo biloba leaf extract on local renin-angiotensin system through TLR4/NF-κB pathway in cardiac myocyte.

Authors:  Hua Jiang; Peng Qu
Journal:  Exp Ther Med       Date:  2017-10-16       Impact factor: 2.447

Review 8.  Role of Muramyl Dipeptide in Lipopolysaccharide-Mediated Biological Activity and Osteoclast Activity.

Authors:  Hideki Kitaura; Masahiko Ishida; Keisuke Kimura; Haruki Sugisawa; Akiko Kishikawa; Kazuhiro Shima; Saika Ogawa; Jiawei Qi; Wei-Ren Shen
Journal:  Anal Cell Pathol (Amst)       Date:  2018-02-14       Impact factor: 2.916

Review 9.  Nod-like receptors: cytosolic watchdogs for immunity against pathogens.

Authors:  Jean-Claude Sirard; Cécile Vignal; Rodrigue Dessein; Mathias Chamaillard
Journal:  PLoS Pathog       Date:  2007-12-28       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.